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Abstract
Polyglutamine (polyQ) diseases represent a neuropathologically heterogeneous group of disorders. The common theme of
these disorders is an elongated polyQ tract in otherwise unrelated proteins. So far, only symptomatic treatment can be
applied to patients suffering from polyQ diseases. Despite extensive research, the molecular mechanisms underlying polyQ-
induced toxicity are largely unknown. To gain insight into polyQ pathology, we performed a large-scale RNAi screen in
Drosophila to identify modifiers of toxicity induced by expression of truncated Ataxin-3 containing a disease-causing polyQ
expansion. We identified various unknown modifiers of polyQ toxicity. Large-scale analysis indicated a dissociation of polyQ
aggregation and toxicity.
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Introduction
The group of polyglutamine (polyQ) diseases comprises nine
dominant heritable neurodegenerative disorders, including Hun-
tington’s disease, spinobulbar muscular atrophy and several
spinocerebellar ataxias (SCA). All nine disorders are caused by
gain-of-function mutations, resulting in an expanded trinucleotide
(CAG) repeat tract, translated into a polyQ expansion in the
respective disease protein. Spinocerebellar ataxia type 3 (SCA3) or
Machado-Joseph disease is the most frequent among the SCA
subtypes, comprising about 21% of the worldwide cases of
autosomal dominant cerebellar ataxias [1]. In SCA3, the disease
protein Ataxin-3 harbors an abnormally elongated polyQ expan-
sion, causative for disease [2]. Such elongated polyQ expansions
are the common theme in various other disorders, the reason why
these disorders are often summarized as polyQ diseases. The
disease-linked proteins share no homology to each other apart
from the polyQ tract, suggesting a common pathogenic mecha-
nism leading to the development of disease. According to the toxic
fragment hypothesis, the polyQ tract itself is the actual toxic
species due to its ability to cause neurodegeneration [3,4,5]. There
is an inverse correlation between repeat number and age of onset.
Additionally, severity of the disease increases with the length of the
CAG tract [6,7]. Expansion of the polyQ stretch in the disease
protein renders the mutant variant prone to aggregation [8]. The
actual inclusions are formed through putative toxic intermediates
[9]. Nevertheless, the toxicity of the different aggregating species is
still under discussion, favoring oligomers of the disease proteins as
the trigger of neuronal dysfunction and eventually neurodegener-
ation [10]. Additionally, nuclear translocation of proteolytically
cleaved polyQ proteins and formation of nuclear inclusions are
early events in pathogenesis and known to be hallmarks in polyQ
diseases [11,12].
Impairment of the ubiquitin-proteasomal system (UPS) seems to
be a key factor in polyQ pathogenesis [13]. UPS activity is needed
to clear aggregates of mutated proteins. Cells with impaired UPS
therefore fail to attenuate the toxic effects of polyQ species [14].
Besides misfolding of the mutant proteins and impaired cellular
protein homeostasis, many other hypotheses have been proposed
to explain polyQ disease pathogenesis. Among these are delete-
rious protein interactions, transcriptional dysregulation, mitochon-
drial dysfunction, impaired axonal transport, anomalous neuronal
signaling and RNA toxicity [15,16,17].
With regard to similar toxicity of heterogeneous proteins in
different cellular and spatial settings, there is overwhelming need
for insight into polyQ protein-interacting genes in order to
decipher the processes involved in neurotoxicity. Drosophila has
proven to be a valuable model organism in research of
neurodegenerative diseases, not least in diverse screening ap-
proaches [18,19,20,21]. Changes in the polyQ-induced rough eye
phenotype (REP) are easily accessible and thus an ideal tool to
perform high-throughput screening for genetic modifiers of polyQ
toxicity. Utilizing an RNAi library comprised of almost all fly
genes having a human ortholog [22], we conducted a Drosophila
screen set to identify genetic interactors of polyQ toxicity.
Computational analysis helped to reveal common pathways of
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the discovered modifier genes, providing insights into possible
disease mechanisms leading to neurodegeneration in polyQ
disorders.
Results
Identification of novel modifiers of polyQ toxicity
Flies with stable expression of an Ataxin-3-derived polyQ tract
(78 glutamines [23]) in all post-mitotic cells of the fly eye
(GMR.polyQ) display a REP characterized by pigment loss, a
disturbed external surface and appearance of necrotic spots. This
easily visible REP is a consequence of degenerating photoreceptors
and other retinal cells (Figure 1A). The severity of the REP has
also been shown to be sensitive towards modifications by second-
site mutations (Figure 1B) [18,19,20,21]. To screen for modifiers of
polyQ toxicity, we used a recently established Drosophila RNAi
library (VDRC) [22]. This library is comprised of transgenes,
expressing inverted repeat sequences forming short hairpin RNAs
under UAS control. Via processing of these double stranded
RNAs, small interfering RNAs are produced, which eventually
leads to silencing of the targeted gene by RNA interference
(RNAi). As we are interested in human disease, we restricted our
analysis to all fly genes of which a human ortholog could be
identified (6,930 genes, full list is available on request) comprising
roughly 45% of all protein coding genes in the fly. First, we tested
if RNAi-mediated silencing of a given gene caused any alteration
of external eye structures. In case GMR-GAL4-driven RNAi
induced changes in adult eyes, these lines were excluded from
future analysis. For the actual screen, GMR.polyQ flies were
crossed to the remaining RNAi lines. In the F1 generation, flies
with combined eye-specific polyQ expression and RNAi-mediated
gene silencing were analyzed for enhancement or suppression of
the REP (Figure 1 B, C). Modifiers were considered as candidates
if obvious changes on polyQ-induced REP were observed. Mild
alterations of the REP appeared frequently and were categorized
as subtle modification. An overview of all candidates is presented
in Table S1. Given the large number of candidates, we were
unable to prove effective silencing of gene expression by RNAi for
all candidates. However, if a target gene was reported to be
required for vitality, we tried to confirm the lethal phenotype by
ubiquitous expression (Act-GAL4) of the respective RNAi trans-
gene. Ubiquitous silencing of these genes caused almost invariably
lethality (82% of genes analyzed), while silencing of the remaining
genes at least resulted in semi-lethality or highly reduced offspring
number (Table S1). Thus, we assume that the majority of the
RNAi transgenes provide efficient silencing of their target.
Modifiers are specific for polyQ-induced toxicity
In our primary screen, we identified a large number of
enhancers and few suppressors of polyQ-induced toxicity
(Figure 1D). Next, we analyzed if the identified modifiers are
specific for polyQ-induced toxicity. Mutations in the tau gene like
Tau[R406W] cause Frontotemporal Dementia and Parkinsonism
linked to chromosome 17 (FTDP-17) [24]. GMR-driven expression
of Tau (WT and FTLD-17-linked mutant variants) results in
REPs, that are also sensitive towards genetic modifications. Such
REPs induced by Tau variants (e. g. WT and V337M) have
previously been used for modifier screens [25,26,27]. Using the
Tau[R406W]-induced REP, we asked if identified polyQ modi-
fiers might have similar effects on Tau-induced toxicity. Interest-
ingly, only 4% of polyQ modifiers (21) similarly affected the Tau-
dependent REP (Table 1). Silencing of these genes might affect the
cell’s folding environment and therefore have an impact on
toxicity of the two aggregation-prone proteins polyQ and
Tau[R406W], respectively. In case of suppressor activity on both
REPs, gene silencing might influence expression strength of the
toxic proteins (Tau[R406W] or polyQ) per se. We therefore
considered these candidates as a separate group. The low number
of candidates showing modification in both disease models implied
that most of the identified modifiers are rather specific for polyQ-
induced toxicity.
Suppression of polyQ-induced toxicity is not restricted to
the retina
Our primary screen was based on retina degeneration.
Consequently, identified modifications might be specific to the
retina. We wanted to test whether our candidates also protect
against polyQ-induced toxicity in neurons different from photo-
receptors. Pan-neural (elav-GAL4) expression of the polyQ construct
used for screening did not result in viable offspring [23]. However,
in combination with identified suppressors, a large portion of
tested suppressors rescued lethality in these flies (Table S2). Thus,
protective effects on polyQ-induced toxicity of the majority of
suppressors are not restricted to photoreceptors but also apply to
other neuron types.
Toxicity does not correlate with polyQ aggregation
Aggregation of proteins containing an elongated glutamine
expansion is a common feature of polyQ diseases
[12,14,28,29,30]. In addition, polyQ aggregation is considered
to be at least partially causative for toxicity. Therefore we assumed
that suppressors of polyQ toxicity identified in our screen might
reduce polyQ aggregation, whereas enhancers might increase
aggregate load. The so-called filter retardation assay is a widely
used method to visualize SDS-insoluble, aggregated polyQ-
containing proteins or peptides (Figure 2A) [31]. The main
number of candidate enhancers (457) caused a lethal interaction in
combination with polyQ expression. Thus, the absence of viable
progeny did not allow to test for aggregation. Nevertheless, we
analyzed remaining modifiers with respect to polyQ aggregation
(Figure 2B, Figure S1). Only 3 of 34 suppressors analyzed showed
a significant reduction of aggregate load. Despite that, the
analyzed suppressors displayed no clear trend with respect to
aggregate load. An increase as well as a decrease of aggregates was
observed. In contrast, most of the analyzed enhancers of polyQ
toxicity displayed a slight reduction in aggregate load. In
summary, we can conclude that obvious changes in toxicity do
not seem to coincide with equivalent changes in aggregate load.
Computational analysis of candidates implies an
involvement of multiple processes in polyQ toxicity
Finally, we performed a computational analysis to identify
cellular processes/pathways, which might be involved in polyQ
toxicity (Figure 3, Figure S2). We first overlaid our candidate genes
onto the meta-interaction network from Costello and co-workers
[32]. We were only interested in those network components that
showed a high degree of clustering. To increase the number of
candidate genes, we included subtle modifiers. Throughout the
primary screen, we categorized suppressors of the polyQ-induced
REP in following groups: (1) wildtype-like, (2) robust and (3) subtle
suppression. Enhancers were categorized in: (5) subtle and (6)
robust enhancement of REP, (7) indicating lethality. Only strong
candidate genes (categories 1, 2, 6, 7) and subtle candidates
(categories 3, 5) that are directly interacting with strong ones were
retained in the network. The resulting network in Figure 3A
consists of 195 genes and 277 interactions. Note that this network
does not represent a cohesive functional module, but only serves to
Modifiers of Polyglutamine Toxicity
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e47452
highlight interacting components with primarily similar functions.
Importantly, this strategy re-discovered a set of proteasomal
proteins (Figure 3A, inset) previously implicated in polyQ toxicity
[33]. The final network graph is available for direct visualization in
Cytoscape (Dataset S1, Cytoscape is available at http://www.
cytoscape.org/download.php).
Assuming that distinct Gene Ontology (GO) functional catego-
ries could be enriched in our different candidate groups, we
treated suppressors (strong/weak), enhancers (strong/weak) and
lethal candidates separately in the analysis of over-represented
terms (Figure 3B). Interestingly, this shows mostly separated
functional categories for the different candidate groups, with some
shared functionality between strong and weak representatives of
enhancers or suppressors, respectively. We therefore also gener-
ated candidate gene lists based on combinations of candidate
groups and tested them for enrichment, using either their explicit
GO annotation (Figure S2, upper panel) or inferred functionality
(Topology Weighted-annotation considering the hierarchy of the
ontology, Figure S2, lower panel) (raw data available in Dataset
S1, the visualization tool Genesis is available at http://genome.
tugraz.at/genesisclient/genesisclient_description.shtml). On the
basis of the more general analysis (Figure 3B), we found
suppressors associated with gamma-Tubulin related molecular
functions, mitosis and transcription. Enhancers seemed associated
with various enzymatic activities and RNA localization, whereas
the group of lethal candidates showed diverse immune-responsive
functions (regulation of stress-activated protein kinase, RNase
complex etc.). The detailed term-by-term analysis of combinations
of candidate groups revealed that phenotypic suppressors
(categories 1+2) confirmed these findings. On the contrary,
enhancers showed relatively weak associations, with the exception
of particularly strong enhancers (category 6), which were enriched
for RNA localization-related GO terms. The strongest degree of
enrichment, however, could be seen for the class of lethal genes
(category 7) that showed significant values for many different GO
terms, ranging from RNA metabolism and localization to not
further specified nuclear functions. The ontology-weighted
approach allowed drilling deeper into the GO hierarchy and
identifying further functional groups that seem relevant in polyQ-
mediated toxicity. Here, enhancers were associated e.g. with
axonal growth cone development and splicing-related activities,
whereas suppressors showed additional involvement in SH2-
domain binding and therefore possibly signal transduction. Again,
a very strong degree of GO enrichment was found for the group of
lethal genes, with nonsense-mediated decay being one of the
strongest terms. Overall, these provide several interesting entry
points for further investigations into polyQ-mediated toxicity.
Figure 1. Screening for modifiers of polyQ-induced toxicity. (A) Rough eye phenotype (REP) used as a primary readout for screening.
Compared to control (upper panels), eye-specific (GMR-GAL4) expression of polyQ (lower panels) induces disturbances of the external eye texture, e.
g. depigmentation of the compound eye observed by light microscopy (left) and as depicted in scanning electron micrographs (middle). Toluidine
blue-stained semi-thin eye sections reveal that the disturbance of external eye structures is accompanied by degeneration of retinal cells (right). (B)
Modification of the polyQ-induced REP by enhancers and suppressors. VDRC transformants used to silence respective genes: CG3284 (11219),
CG16807 (23843), CG15399 (19450) and CG7843 (22574). (C) Flow chart of the screening procedures to identify modifiers of polyQ-induced toxicity.
(D) Brief summary of screen results. Scale bars represent either 200 mm in eye pictures or 50 mm in semi-thin eye sections.
doi:10.1371/journal.pone.0047452.g001
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Discussion
To our knowledge, the present screen for modifiers of polyQ
toxicity comprises the largest number of genes analyzed in such
assays. Usage of the VDRC RNAi library allows large-scale,
almost genome-wide screening. However, RNAi-mediated gene
silencing approaches might cause off-target effects. Although the
VDRC library was designed to limit off-target effects, we are
aware that some of our candidates might result from off-target
effects. Additionally, RNAi lines used in this screen were generated
by random integrations of UAS-RNAi constructs into the fly
genome. Consequently, we cannot exclude the possibility that the
site of transgene insertion rather than the RNAi effect itself caused
the observed modification on the polyQ-induced REP. In our
screen, the plethora of individual RNAi lines and the high number
of candidates prevented us to test for potential off-target and/or
genetic background effects. Apart of these drawbacks, using RNAi
libraries has certain advantages to screen for modifiers of polyQ-
induced induced toxicity. For example, previous screens on
modifiers of polyQ-induced REPs utilized P-element gene
disruption or EP-element-driven overexpression/silencing of genes
[18,19,20]. Although these screens provided valuable insights in
the mechanisms of polyQ-induced toxicity, a drawback of P/EP-
element-based screens is the limited amount of available elements
and the unknown/low number of targeted genes. The expected
low number of assayed genes might explain the small overlap of
candidates identified by Bilen and Bonini [18] with our screen
(Figure 4). In addition, we compared our data with selected RNAi
screens for modifiers of polyQ aggregation performed in cultured
insect cells [34] and in C. elegans [35]. Although the primary
readout has been aggregation rather than toxicity, several
common candidates were identified in comparison with our
screen. To our surprise, the overlap of the two aggregation screens
[34,35] was as high as with our screen (Figure 4). In a next step, we
grouped overlapping candidate genes according to the reported
function of their gene products. Almost all common candidates
could be assigned to the following three categories: 1. Protein
turnover/quality control (Trp2, DnaJ-1, Hop, Hsc70Cb, Hsc70-4,
Prosß2, etc); 2. Nuclear import/export (emb, Ntf-2 and CG5738) and
3. mRNA transport/editing/translation (orb, Nelf-E, Prp8, etc).
These results suggest that impairment of these processes might
contribute to disease. This is in line with previous reports showing
a strong involvement of the UPS in polyQ toxicity
[14,36,37,38,39,40]. In addition, network analysis of our candi-






Predicted molecular function/biological process (as listed on
flybase.org)
Rab30/CG9100 E E GTPase activity/involved in vesicle sorting and transport
Aats-his/CG6335 E E histidine-tRNA ligase/histidyl-tRNA aminoacylation
MED14/CG12031 E E protein binding/transcription from RNA polymerase II promoter
Prp8/CG8877 E E unknown/nuclear mRNA splicing, via spliceosome
Nelf-E/CG5994 E E mRNA binding/negative regulation of transcription from RNA polymerase
II promoter during mitosis
RpS10a/CG12275 E E Structural constituent of ribosome/neurogenesis
-/CG11985 E E unknown/mitotic spindle organization
Prosbeta2/CG3329 E E endopeptidase activity/catalytic constituent of the proteasome (beta-
subunit), protein degradation
Rpn9/CG10230 E E endopeptidase activity/regulation of exit from mitosis, protein
degradation
bic/CG3644 E E unknown/regulation of establishment of protein localization, RNA
binding, intracellular mRNA localization
MRG15/CG6363 S S unknown/chromatin silencing
Hop/CG2720 S S unfolded protein binding/protein folding
-/CG6364 E E Uridine kinase activity/phagocytosis, engulfment
-/CG6873 E E Actin binding, polymerization/neurogenesis
Nrx-IV/CG6827 E E transmembrane signaling receptor activity/dorsal closure; nerve
maturation; regulation of tube size, open tracheal system; establishment
of glial blood-brain barrier; septate junction assembly; axon
ensheathment.
CycJ/CG10308 E E cyclin-dependent protein kinase regulator activity/mitotic cell cycle,
embryonic; mitosis
-/CG8086 E E unknown/neurogenesis
bru/CG2478 E E unknown/cytokinesesis
-/CG8108 E E zinc ion binding/unknown
vnc/CG11989 E E peptide alpha-N-acetyltransferase activity/oogenesis, neurogenesis
Smg5/CG8954 E E unknown/nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay
Table lists gene name (if applicable) and gene ID of all candidates identified to have a similar effect on polyQ- and Tau-induced REPs. Mode of modification is indicated
(enhancement (E), suppression (S)). A brief summary of the molecular and biological functions assigned to the identified gene products is listed.
doi:10.1371/journal.pone.0047452.t001
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dates implies an enrichment of proteasomal components high-
lighting the importance of the proteasome in polyQ disease
(Figure 3). Moreover, translocation of polyQ peptides into the
nucleus is believed to be an important step in disease
[23,28,29,41,42,43,44]. Finally, mRNA transport/editing/trans-
lation is crucial for cell fitness and tightly regulated. This
regulation often takes place in response to or as compensation of
cellular stress [45,46]. The fact that only few of these candidates
also had an impact on Tau-induced toxicity, suggests that the
regulation of these pathways is rather specific for polyQ-induced
toxicity. Heat shock proteins/chaperones like Hsc70-4, Hsc70-1
and Hop are considered to provide protective effects on toxicity
exerted by aggregation-prone proteins. Indeed, overexpression of
human HSP70 suppresses polyQ toxicity [47,48]. The tight
regulation of heat shock protein (HSPs)/chaperone expression by
auto-regulatory mechanisms might explain why silencing of some
HSPs suppressed polyQ-induced toxicity. For example, the
initiation of HSP transcription by heat stress transcription factor
1 (HSF1) is prevented by direct binding of HSP90 to HSF1 [49].
In agreement with previous reports, our analysis on polyQ
aggregation of selected candidates revealed a dissociation of
toxicity and aggregation [11,50,51]. We found that only a minor
portion of analyzed suppressors had a significant effect on polyQ
aggregation. More precisely, suppressors caused either a reduction
or an increase of aggregated polyQ species compared to control, as
visualized by filter retardation assay (Figure 2, Figure S1). We are
aware that the filter retardation assay might not perfectly reflect
actual aggregate load. According to the pore size of the membrane
(0.2 mm), we might not be able to detect aggregates with a
diameter smaller than the pore. In addition, we might pellet
extremely high molecular weight aggregates by centrifugation
steps in sample preparation and thus deplete these aggregate
species from our analysis. In case of the analyzed enhancers, there
was no clear trend towards increased aggregation (Figure 2B,
Figure S1). In contrast, almost all analyzed enhancers displayed a
slightly reduced aggregate load. However, the high degree of
retina cell loss observed for enhancers might bias the actual
aggregate load due to a reduction in the absolute number of
polyQ-expressing cells present at the time of analysis. In summary,
our findings nevertheless imply absence of correlation between
toxicity and aggregation. This was at least partially unexpected as
previous analyses implicated such a correlation and convincingly
proved this assumption with a wide range of experimental
approaches [52,53]. A smaller sample number in previous reports
might account for the discrepancy compared to our analysis.
The computational analysis of our candidate gene set highlights
the broad range of molecular functions that might affect polyQ-
mediated toxicity. The network-based approach utilizes subtle
phenotypic changes of some candidates to tie links between strong
candidate genes. While not all subtle candidates may be ‘true’, a
good proportion actually does make sense in the light of the
network- and Gene Ontology analysis. A future challenge will be
Figure 2. Analysis of polyQ aggregate load. (A) Exemplified filter
retardation analysis to visualize polyQ aggregates. Decreasing amounts
of loaded protein derived from fly heads of control (GMR-GAL4, top),
GMR.polyQ (middle) or GMR.polyQ in combination with a candidate
suppressor (bottom). (B) Densitometric measures of filter retardation
analysis. Data depicted as fold change compared to control (GMR.po-
lyQ) for suppressors and enhancers of polyQ-induced toxicity.
Independent homogenates (if available) were used for repetitions. In
case of none or only one independent repetition n#2 is indicated. In all
other cases, number of independent repetitions is n$3. Significant
changes are indicated * p,0.05; *** p,0.001.
doi:10.1371/journal.pone.0047452.g002
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the identification and assessment of the most important functional
categories that might moderate polyQ-induced toxicity.
Methods
Flies were raised and maintained on standard cornmeal-agar-
yeast food. If not stated otherwise, all crosses were performed at
25uC. The ‘‘human ortholog RNAi library’’ (status October 2007)
was obtained from the Vienna Drosophila RNAi Center (VDRC).
Selection of human orthologs was done by the VDRC using
common databases. Filter criteria were not provided. RNAi lines
for confirmation were provided by the Bloomington Drosophila
Stock Center (BDSC, USA) or the National Institute of Genetics
(NIG-fly, Japan). Non-RNAi lines: w[*]; P{w[+mC]=UAS-
Hsap\MJD.tr-Q78}c211.2 (BDSC 8150; allows expression of HA-
tagged C-terminal fragment of Ataxin-3 with a 78 repeat polyQ
tract; referred to in text as polyQ); w[*]; P{w[+mC]= longGMR-
GAL4} (BDSC 8605; referred to as GMR-GAL4 in text). Additional
fly strains used: w[*]; P{Act5C-GAL4}/CyO driver (Act-GAL4 in
text, provided by the Herbert Ja¨ckle laboratory),
P{w[+mW.hs] =GawB}elav[C155] (BDSC 458, elav-GAL4 in text)
and w[*];; P{w[+mC]=UAS-hTau[R406W]} (kindly provided by
Mel Feany).
Screening was performed using flies in which the GMR-GAL4
driver was recombined with the polyQ transgene (w[*];
P{w[+mC]= longGMR-GAL4}, P{w[+mC]=UAS-Hsap\MJD.tr-
Q78}c211.2/CyO; GMR.polyQ in text). GMR.polyQ virgins were
crossed to males carrying UAS-RNAi constructs. F1 females
(GMR.polyQ in combination with respective UAS-RNAi expres-
sion) were selected for REP evaluation 1–5 days post eclosion.
Effects on the polyQ-induced REP were categorized in following
groups:
(1) wildtype-like suppression, (2) robust suppression, (3) subtle
suppression, (4) no change, (5) subtle enhancement, (6) robust
enhancement, and (7) lethal.
Only strong modifiers (categories 1, 2, 6, 7) were verified thrice
and then considered as candidates. Subtle modifiers were only
included in computational analyses.
Rescue of lethality following pan-neural polyQ expression was
assayed at 29uC. In a first step, elav-GAL4 virgins with balanced 2nd
(Sco/CyO) or 3rd (CxD/TM3) chromosomes were crossed to flies
harboring respective 2nd or 3rd chromosomal UAS-RNAi trans-
genes. In the F1 generation, males carrying elav-GAL4 in
combination with balanced UAS-RNAi transgenes (elav-GAL4/Y;
UAS-RNAi/CyO or elav-GAL4/Y;; UAS-RNAi/TM3) were selected
and crossed to homozygous polyQ virgins. Presence of female
offspring was monitored in the F2 generation.
Filter retardation assays for evaluation of polyQ aggregate
load were mainly conducted as described [31,53]. Briefly, fly heads
were lysed in RIPA buffer (50 mM Tris, pH 8.0, 0.15 M NaCl,
0.1% (v/v) SDS, 1% NP-40, 0.5% Sodium deoxycholate, Protease
inhibitor (Roche)). 15 mg protein from fly head homogenates (DC
Protein Assay Kit, BIO-RAD) were subjected with 16 dot blot
buffer (20% (v/v) Glycerol, 0.2 M DTT, TRIS-HCl, pH 6.8) and
boiled (5 min). Using a dot blot filtration unit, lysates were filtered
through a nitrocellulose membrane (Whatman, pore size 0.2 mm)
equilibrated with 0.1% SDS in TBS (25 mM Tris, 140 mM NaCl,
pH 7.5) and afterwards washed in TBS+0.05% Tween-20. The
membrane was probed with mouse anti-HA antibody (Covance,
Figure 3. Computational analysis of modifiers of polyQ-
induced toxicity. (A) Meta-interaction network displaying modifiers
of polyQ toxicity. Only candidates causing a robust modification of the
REP (red) as well as directly interacting subtle modifiers (black) were
retained from an initial network of more than 5 k genes with 20 k
interactions [32]. One local cluster of functionally interacting modifiers
is highlighted. (B) Gene Ontology analysis of these candidate gene
groups. Shown are -log10(p-value) scores for GO term enrichment for
candidate gene groups (horizontal axis, see inset for group identities)
and GO term (vertical). The matrix incorporates the structure of the GO
hierarchy and is based on the Topology Weighted Term-algorithm as
implemented in Ontologizer (terms with a p-value,0.005 are shown).
doi:10.1371/journal.pone.0047452.g003
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1:1,000) and secondary HRP-coupled antibody (GE Healthcare,
1:10,000). ECL solution was used for visualization. Independent
homogenates (if available) were used for repetitions. In case of
none or only one independent repetition n#2 is indicated. In all
other cases, number of independent repetitions is n$3. In
addition, regular Western blots of head lysates were probed with
Syntaxin antibody (DSHB 8C3 1:2,500) to control for equal
protein loading. Statistics: Variation within the data set was tested
independently for suppressors and enhancers with ANOVA. If
variation was significant, Bonferroni post-hoc test was applied
(GraphPad Prism 5).
Computational analyses were performed primarily with
custom-written Perl scripts. The network graph on the basis of the
meta-interaction network [32] was generated using Cytoscape v2.8
[54]. Gene Ontology over-representation statistics were calculated
using the command line version of Ontologizer v2.0 [55], using
the set of tested RNAi lines as background population. The
resulting matrix of candidate gene groups and Gene Ontology
terms was clustered and displayed using Genesis v1.76 [56].
Supporting Information
Figure S1 Filter retardation and Western blot analysis
of selected head lysates. Filter retardation assay (FRA) was
used to visualize polyQ aggregates. Western blot (WB) analysis of
the head lysates to monitor abundance of Syntaxin was used for
normalization purposes. Transformant IDs of selected suppressors
and enhancers of polyQ-induced REPs are indicated.
(TIF)
Figure S2 Gene Ontology analysis of candidate gene
groups. Shown are 2log10(p-value) scores for GO term
enrichment for each non-redundant combination of candidate
gene groups (horizontal axis) and GO term (vertical). The analysis
incorporated all possible combinations of subtle, strong and lethal
candidate groups. The range of phenotypes was categorized: 1 full,
2 robust and 3 subtle suppression of REP, 5 subtle and 6 robust
enhancement of REP, 7 indicating lethality. The upper matrix is
based on simple term by term comparison for GO term
enrichment with a Benjamini/Hochberg-corrected p-value,0.15.
While the first approach yielded vastly redundant terms of
primarily nuclear processes, the latter approach (Topology
Weighted-annotation considering the tree hierarchy of the
ontology, lower matrix) uncovered potential molecular functions
as distinct as splicing and transmembrane receptor signaling.
(TIF)
Table S1 Identified obvious modifiers of the SCA3tr-
Q78-induced REP. Table lists transformant ID (from VDRC),
gene ID and gene name (if applicable) of all candidates identified
along with the observed effects on the SCA3-induced phenotype:
wildtype-like suppression (S*), robust suppression (S), robust
enhancement (E), or lethal interaction (lethal). PolyQ modifiers
Figure 4. Overlap between screens for genetic modifiers of polyQ-induced toxicity or aggregation. The Venn-like diagram displays only
candidate genes shared by the different screens. Mode of modification (enhancement/suppression) is not addressed, due to the different readouts
(aggregation/toxicity), model systems (Drosophila, insect cells, C. elegans) and elongated polyQ-containing proteins used in the diverse screening
approaches.
doi:10.1371/journal.pone.0047452.g004
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with similar effects on Tau[R406W]-induced toxicity are high-
lighted in grey. Essential genes with amorphic mutations known to
cause lethality are indicated (1). Reduced vitality or lethality
following ubiquitous shRNA (actin5C-GAL4) against these genes is
indicated in red. Lines not available for re-screening and/or
photographs are marked as not analyzed (n.a.).
(DOC)
Table S2 Rescue of lethality induced by pan-neural
polyQ expression. Table lists transformant ID (from VDRC),
gene ID and gene name (if applicable) of all RNAi lines (genes
silenced) which were tested for rescue effects on elav.polyQ-
induced lethality. In the F1 generation (elav.polyQ in combination
with respective RNAi line), effects of gene silencing were
categorized as rescue (R) if vital offspring was observed, or lethal
(L) if no vital offspring was present. Control (white RNAi) is marked
in grey. Lines not available for rescue experiments are marked as
not analyzed (n.a.).
(DOC)
Dataset S1 Raw data archive in ZIP format. Supplemen-
tary File F1.cys for visualization in Cytoscape contains a network
graph with RNAi screen candidates mapped onto the 20 k
network of Costello et al. 2009. Primary candidates are
represented in red, subtle candidates in black. The two
Term2TermGOTerms as well as the two TopologyWeight-
edGOTerms files contain GO enrichment statistics and clustering
results, and can be directly loaded into Genesis for visualization.
(ZIP)
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